SLGL

Sol-Gel Technologies Ltd.

Nasdaq · Pharmaceutical Preparations · Inc. L3 · CIK 0001684693
$80.00 +2.59% $224.8M
Vol
Market Cap$224.8M
Cap SizeMicro Cap
Insider Activity5B / 0S
Insider Net $$2.8M
SEC Reports3
Press Releases1
Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. L3·CIK 0001684693·Prev Close $77.98

Recent Activity

May 28, 2026 SEC
Sol-Gel reported Q1 2026 revenue of $0.1M (down 89.5% YoY from $1.0M) and a net loss of $3.7M ($1.31/share), improved fr
6-K — Impact 6/10
May 28, 2026 SEC
Sol-Gel reported Q1 2026 EPS of -$1.31, a 62.6% beat vs consensus of -$2.86, but revenue fell 90% YoY to $0.1M due to a
PRESS-RELEASE — Impact 6/10
May 28, 2026 earnings
Sol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updates
<p>NESS ZIONA, Israel, May 28, 2026 (GLOBE NEWSWIRE) -- <strong>Sol-Gel Technologies, Ltd.</strong
May 20, 2026 Insider
Opaleye Management Inc. bought 1,563 shares
10%+ Owner @ $64.43 ($100.7K)
May 13, 2026 Insider
Opaleye Management Inc. bought 1,937 shares
10%+ Owner @ $66.87 ($129.5K)
May 12, 2026 Insider
Opaleye Management Inc. bought 1,500 shares
10%+ Owner @ $67.98 ($102.0K)
Mar 24, 2026 SEC
Sol-Gel Technologies Ltd. (SLGL) has received SEC effectiveness for its registration statement, allowing it to proceed w
EFFECT — Impact 4/10
Mar 19, 2026 Press
Sol-Gel Technologies filed its 20-F for 2025, disclosing audited financial results and providing corporate updates. The
Impact 4/10

Price Targets

Historical data — last covering-analyst action Jan 2026. No current recommendation available.
$147.00 (Jan 2026)
Current $76.22 Low $110.00 Median $147.00 High $184.00 2 analysts
$110.00 $184.00

Analyst Ratings

Historical distribution88% buy · 8 analysts · last covering-analyst action Jan 2026
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
DateFirmActionRating
Jan 20, 2026 HC Wainwright & Co. MAINTAIN Buy → Buy
Dec 22, 2025 HC Wainwright & Co. REITERATE Buy → Buy

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $-3.33 ▼ -84.0% $-3.33 — $-3.33 1
Next Q $-3.45 ▼ -93.8% $-3.45 — $-3.45 -62% YoY 1
Current FY $-8.26 ▼ -21.3% $-13.03 — $-4.95 -277% YoY 3
Next FY $-10.88 $-16.81 — $-4.95 -32% YoY 2

Recent Insider Trades

DateInsiderTypeValue
May 20, 2026Opaleye ManagementBUY$100.7K
May 13, 2026Opaleye ManagementBUY$129.5K
May 12, 2026Opaleye ManagementBUY$102.0K
Mar 24, 2026Opaleye ManagementBUY$2.5M
Feb 2, 2026Opaleye ManagementBUY$5.8K

No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.

1 unique insiders with 5 transactions. Net insider value: $2.8M ($2.8M bought, $0.00 sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
May 20, 2026Opaleye Management Inc.10%+ OwnerBUY1,563$64.43$100.7K
May 13, 2026Opaleye Management Inc.10%+ OwnerBUY1,937$66.87$129.5K
May 12, 2026Opaleye Management Inc.10%+ OwnerBUY1,500$67.98$102.0K
Mar 24, 2026Opaleye Management Inc.10%+ OwnerBUY34,665$72.00$2.5M
Feb 2, 2026Opaleye Management Inc.10%+ OwnerBUY100$58.00$5.8K
Historical analyst distribution (last covering-analyst action Jan 2026): 88% buy across 8 analysts — 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.

Analyst Price Targets

Historical data — last covering-analyst action Jan 2026. No current recommendation available.
$147.00 mean target (Jan 2026)
$110.00 Low $184.00 High
MetricValue
Current Price$76.22
Target Low$110.00
Target Mean$147.00
Target Median$147.00
Target High$184.00
# Analysts2
Recommendation— (no recent coverage)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
$-3.33 $-3.33 $-3.33 -84.0% $0.0B 1
Next Q
2026-09-30
$-3.45 $-3.45 $-3.45 -62.0% -93.8% $0.0B 275.0% 1
Current FY
2026-12-31
$-8.26 $-13.03 $-4.95 -277.3% -21.3% $0.0B -100.0% 3
Next FY
2027-12-31
$-10.88 $-16.81 $-4.95 -31.7% 0↑ 1↓ $0.0B 0.0% 2

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$-3.330
7d ago$-2.900-0.430
30d ago$-1.810-1.520
60d ago$-1.810-1.520
90d ago$-1.810-1.520
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.

Historical Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
Jan 20, 2026 HC Wainwright & Co. MAINTAIN Buy Buy
Dec 22, 2025 HC Wainwright & Co. REITERATE Buy Buy

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20262510088%
May 1, 20262410086%
Apr 1, 20262410086%
Mar 1, 20262410086%
Feb 1, 20262410086%
Jan 1, 20262410086%
Strong BuyBuyHoldSellStrong Sell

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

May 28, 2026
earnings
Sol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updates
<p>NESS ZIONA, Israel, May 28, 2026 (GLOBE NEWSWIRE) -- <strong>Sol-Gel Technologies, Ltd.</strong> (NASDAQ: SLGL), a dermatology company, pioneerin
May 21, 2026
earnings_calendar
SLGL Q1 2026 Earnings Scheduled — 2026-05-21
May 11, 2026
Clinical Trial
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome
Phase Phase 3 — ACTIVE_NOT_RECRUITING
May 11, 2026
clinical_trial_readout
T-90d Trial Readout: Patidegib Topical Gel (Phase 3)
Trial: Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome Sponsor: Sol-Gel Techno
May 4, 2026
clinical_trial_readout
T-90d Trial Readout: Patidegib Topical Gel (Phase 3)
Trial: Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome Sponsor: Sol-Gel Techno
May 3, 2026
clinical_trial_readout
T-90d Trial Readout: Patidegib Topical Gel (Phase 3)
Trial: Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome Sponsor: Sol-Gel Techno
Mar 24, 2026
other
Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering
Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering
Mar 23, 2026
earnings_calendar
SLGL Q4 2025 Earnings After Market Close — 2026-03-23
Mar 19, 2026
earnings
Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025
Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025